Taf + Emtricitabine + Darunavir + Cobicistat Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: Darunavir- 800 mg + Cobicistat-1 50 mg + Emtricitabine- 200 mg + TAF-10 mg
Reference Brands: Symtuza(Eu & US)
Category:
Anti Viral
Symtuza is a once-daily, complete HIV-1 treatment with Darunavir, Cobicistat, Emtricitabine, and TAF. FDA and EMA approved, it offers high resistance protection and improved safety in a single-tablet regimen.
TAF + Emtricitabine + Darunavir + Cobicistat is available in Tablet
and strengths such as Darunavir- 800 mg + Cobicistat-1 50 mg + Emtricitabine- 200 mg + TAF-10 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, TAF + Emtricitabine + Darunavir + Cobicistat is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
TAF + Emtricitabine + Darunavir + Cobicistat can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Symtuza is the first once-daily, single-tablet regimen combining Darunavir 800 mg, Cobicistat 150 mg, Emtricitabine 200 mg, and Tenofovir Alafenamide (TAF) 10 mg for the treatment of HIV-1 infection. Approved by both the FDA and EMA, Symtuza is indicated for adults and adolescents (≥12 years, ≥40 kg) who are treatment-naïve or virologically suppressed. The high resistance barrier of Darunavir, boosted by Cobicistat, makes Symtuza ideal for durable viral suppression. Its TAF backbone ensures better renal and bone safety than older TDF-based regimens. Symtuza offers the simplicity of a PI-based single-tablet regimen, enhancing long-term adherence.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing